Cione Erika, Abrego-Guandique Diana Marisol, Chiari Aldo, Cannataro Roberto
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Cosenza, Italy.
Galascreen Laboratories - University of Calabria, Cosenza, Italy.
Front Aging. 2025 Jul 30;6:1554340. doi: 10.3389/fragi.2025.1554340. eCollection 2025.
Over the last 20 years, increased life expectancy has been observed in men and women, resulting in a rise in the prevalence of diseases among the aging population. From this, sarcopenia has an estimated prevalence of 10%-16% of older people worldwide. Losing strength and muscle mass in the 65-70 age group represents a significant public health problem. In this review, we emphasize the essential importance of strength training in managing sarcopenia, highlighting the role of microRNAs, small nucleotides that were the subject of last year's Nobel Prize in Physiology or Medicine. These microRNAs regulate protein synthesis and are present in all biological fluids. Some of them are expressed differently by subjects affected by sarcopenia (as happens in various forms of cancer or other diseases). Therefore, monitoring a specific signature of microRNAs can better clarify the etiopathology of sarcopenia, providing an early biomarker for sarcopenia (currently, there are some hypotheses, but none is well recognized), and even serve as the basis for the development of drugs.
在过去20年里,男性和女性的预期寿命均有所增加,导致老年人群中疾病的患病率上升。由此,全球范围内老年人肌少症的患病率估计为10%-16%。65至70岁年龄段人群出现力量和肌肉量流失是一个重大的公共卫生问题。在本综述中,我们强调力量训练在管理肌少症方面的至关重要性,突出了微小RNA的作用,微小RNA是一类小核苷酸,也是去年诺贝尔生理学或医学奖的主题。这些微小RNA调节蛋白质合成,并且存在于所有生物体液中。其中一些在受肌少症影响的受试者中表达不同(如同在各种癌症或其他疾病中那样)。因此,监测微小RNA的特定特征可以更好地阐明肌少症的病因病理,为肌少症提供一种早期生物标志物(目前有一些假说,但尚无一种得到广泛认可),甚至可作为药物研发的基础。